Novadaq's SPY tech labelling:
This article was originally published in Clinica
Executive Summary
The US FDA has given Novadaq Technologies 510(k) clearance to revise the labelling of its SPY intra-operative imaging system, a fluorescence-based guided technology that enables cardiac surgeons to visually assess coronary vasculature and bypass graft functionality during open-heart bypass surgery. The revision allows direct injection of the imaging agent to the vessels in the region of interest, giving the surgeon greater flexibility without posing any additional risk to the patient, said the Toronto, Canada firm. In addition, the company has also begun two additional clinical trials in different therapeutic applications for SPY - cerebral angiography during neurosurgery and the evaluation of access points for renal failure patients undergoing haemodialysis. Applying the imaging platform to different therapeutic areas, with no significant investment in technology, demonstrates the potential to expand the market opportunity for Novadaq, the firm said.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.